Inclusion Criteria:  Male subjects with a diagnosis of mild to moderate acne vulgaris, defined as an Investigator's global assessment (IGA) score of 2-3; Chronic course of acne vulgaris; Acne-related lesions both on the face, chest and back; Indication for treatment of acne vulgaris; Aged 18-30 years (inclusive); Fitzpatrick skin types I-III; Providing written Informed Consent prior to the performance of any study-specific procedure.  Exclusion Criteria:  Female subjects; Diagnosis of severe acne vulgaris; Allergy to afamelanotide or the polymer contained in the implant or to lidocaine or other local anesthetic to be used during the administration of the implant; Use of topical acne medication such as retinoids, benzoyl peroxide or topical antibiotics within 2 weeks prior to the first dose; Use of oral antibiotics for acne within 4 weeks prior to the first dose; Use of topical corticosteroids on the face, chest and back or systemic corticosteroids within the past 4 weeks prior to the first dose; Use of systemic retinoids within 6 months prior to the first dose; Use of anti-androgenic agents such as finasteride within 4 weeks prior to the first dose; Use of phototherapy devices for acne such as ClearLight™ or Zenozapper within 1 week prior to the first dose; Use of tanning booths or lamps within 1 week prior to the first dose; Active skin disease that may interfere with evaluation; Other forms of acne such as acne rosacea, acne excoriée, chloracne, acne conglobata, acne fulminans, acne inversa or drug-induced acne; Participation in a clinical trial for an investigational agent within 30 days prior to the screening visit.